



PARABOLIC DRUGS LIMITED

Parabolic Drugs' 9M FY12 sales up 54.39% to Rs 719.51 crore Net Profit up 13.66% to Rs. 42.39 Crore Initiates production for the Life style drugs at its Lalru facility

9M FY12 Results Media Release

BSE Code: 533211
NSE Code: PARABDRUGS

FY11 Sales: Rs. 675.30 crore
5 year CAGR: 41.84%
FY11 Net Profit: Rs. 52.87 crore
5 year CAGR: 39.71%

Headquartered in Chandigarh, with three manufacturing facilities – two in Punjab and one in Haryana; a world-class custom synthesis and R&D centre at Barwala, (Haryana)

1400+ employees including R&D Team of 100 Scientists

Product portfolio comprising of 44 APIs and 7 API intermediates; filed 38 Drug Master Files

Aiming to emerge as a Global Pharmaceuticals Company by 2015

For more information:

Sameer Madan
Vice President- Trade Finance
Parabolic Drugs, Chandigarh
sameer.madan@parabolicdrugs.com
+ 91 172 391 4658

Parthajeet Sarmah
Christensen
psarmah@christensenir.com
+91 98670 01356

Chandigarh, February 11, 2012: Parabolic Drugs Ltd., a vertically integrated API manufacturer and exporter in India, today announced the unaudited results for quarter ended 31st December, 2011.

Q3FY12 Performance

- The Company's sales increased by 81.71% to Rs. 298.85 crore as compared to Rs. 164.46 crore in Q3 FY 11. Out of the total sales in Q3FY12, the manufacturing sales are Rs. 170.56 crore while the outsourcing sales are Rs. 128.29 crore.
- The outsourcing of products will generate additional capacities that will be utilized for producing higher value molecules.
- Net profit at Rs. 12.82 crore as compared to Rs. 12.48 crore in Q3 FY 11
- EBITDA increased by 33.05% to Rs. 42.05 crore as compared to Rs. 31.61 crore in Q3 FY 11

9M FY12 Performance

- Sales increased by 54.39% to Rs. 719.51 crore during 9MFY12 as compared to Rs. 466.04 crore in 9MFY11
- Net profit up 13.66% at Rs. 42.39 crore as compared to Rs. 37.30 crore in 9MFY11
- EBITDA increased by 45.25% to Rs. 126.43 crore in 9MFY12
- The company's EBITDA margin stood at 19.37% while net margins were at 6.50%

Major operational highlights for Q3 FY 12

During the Q3 FY 12, the company has initiated production at its greenfield site in Lalru for the development of lifestyle drugs and non-antibiotics. The site is spread across 27 acres, dedicated to manufacture non-antibiotic APIs in the new therapies such as CVS, CNS, oncology, antithrombotic, anti-diabetic and pain management. The company is planning eight molecules to be launched in the upcoming quarters with a total product pipeline of 17 molecules to be launched from this site over a three-year period. There has been considerable increase in the regulated sales, with 41% regulated exports to total direct exports. The upsurge has largely come due to increased sales to Germany, Switzerland, Turkey, Italy, Netherland and China. In the formulations pace, under its division 'Nucleus', the company now has a wide basket in all finished forms for over 130 products across different therapies with a distribution network of 16 distributors, 469 stockiest in over 20 states.



PARABOLIC DRUGS LIMITED

Management comment

Commenting on the performance, Mr. Vineet Gupta, Director, Parabolic Drugs, said, “We are extremely pleased with another strong performance this quarter. The commencement of production at the Lalru facility adds an entirely new dimension to the Company by catering to the high growth niche segments. We are confident that this momentum will continue in the next quarter and lay the foundation for a strong FY 13.”

About Parabolic Drugs Ltd.

Parabolic Drugs Ltd., incorporated in 1996, is promoted by professionally qualified first generation entrepreneurs. It is engaged in manufacturing, including contract manufacturing, of APIs and API intermediates for domestic and international markets, including regulated markets. It manufactures Semi Synthetic Penicillin (“SSP”) and Cephalosporin range of antibiotics, whereby the product portfolio comprises 44 APIs and 7 API intermediates. The company has two manufacturing facilities located at Derabassi, Punjab and Panchkula, Haryana. It also has a custom synthesis and R&D centre at Barwala, Haryana, which started operations in January 2010. Proposed facilities include a manufacturing facility for non-antibiotic products at Chachrauli, Derabassi and another custom synthesis and manufacturing site at Panchkula being set up by PDL’s subsidiary.